How Ph.D. was paid
$1.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Hans T. Schambye, M.D., Ph.D.Former President and Chief Executive Officer | $547,521 | $678,594 | $73,677 | $0 | $1,299,792 |
| Lori FirmaniChief Financial Officer | $311,249 | $202,500 | $22,463 | $27,000 | $563,211 |
| Garrett WinslowGeneral Counsel | $400,400 | $400,400 | $26,955 | $27,000 | $854,755 |
What changed and why
- $1.3MFormer CEO Hans T. Schambye received total compensation of $1,299,792 for fiscal 2025.
- $1.4MCEO total compensation decreased compared to the prior fiscal year total of $1,429,550.
- $375KLori Firmani was appointed Chief Financial Officer with a base salary increase to $375,000.
- Executive compensation included annual performance bonuses and retention bonus awards earned in 2025.
Other Damora Therapeutics proxy statements
- 2025 proxy statement
Hans T. Schambye, M.D., Ph.D. paid $1.4M (+48% on the year).
Filed Dec 31, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.